{"id":1062,"date":"2022-01-26T15:07:53","date_gmt":"2022-01-26T20:07:53","guid":{"rendered":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/?page_id=1062"},"modified":"2022-02-24T12:57:50","modified_gmt":"2022-02-24T17:57:50","slug":"prelude-summit","status":"publish","type":"page","link":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/","title":{"rendered":"Prelude Summit"},"content":{"rendered":"<style>\r\n.content-event-page .page-header { display:none; }\r\n.anchor { position:absolute; margin-top:-120px; }\r\n<\/style>\r\n\r\n<a href=\"https:\/\/hopin.com\/events\/c5s-virtual-forum-on-pharma-and-biotech-patent-litigation-in-europe\" rel=\"noopener noreferrer\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg\" alt=\"\" width=\"1200\" height=\"627\" class=\"alignnone size-full wp-image-1063\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg 1200w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-300x157.jpg 300w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-768x401.jpg 768w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-1024x535.jpg 1024w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-1160x606.jpg 1160w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-960x502.jpg 960w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-760x397.jpg 760w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-660x345.jpg 660w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-460x240.jpg 460w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-360x188.jpg 360w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-260x136.jpg 260w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-160x84.jpg 160w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-60x31.jpg 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-150x78.jpg 150w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit-80x42.jpg 80w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><\/a>\r\n<br>\r\n<h3><strong>Day One<\/strong>&nbsp;&nbsp;|&nbsp;&nbsp;<a href=\"#day-two\"><strong>Day Two<\/strong><\/a><\/h3>\r\n\r\n<table>\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:0px 0px 20px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\" width=\"80\">\r\n      <p>12:10<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>Opening Remarks from the Co-Chairs<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-80x80.jpg\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-80x80.jpg 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-130x130.jpg 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-60x60.jpg 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom.jpg 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tDominic Adair\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Bristows LLP (U.K)<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n\t<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-80x80.gif\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-80x80.gif 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-130x130.gif 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-60x60.gif 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden.gif 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tRuud van der Velden\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Hogan Lovells<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>12:15<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>UPC Think Tank: Ratification, Implementation, and Protocols<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Domien-Op-de-Beeck-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Domien-Op-de-Beeck-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Domien-Op-de-Beeck-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Domien-Op-de-Beeck-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Domien-Op-de-Beeck.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tDomien Op de Beeck\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Bird &amp; Bird<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Jochen-Herr-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Jochen-Herr-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Jochen-Herr-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Jochen-Herr-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Jochen-Herr.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tJochen Herr\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n      <p>The Unitary Patent and the Unified Patent Court have been designed to bring forth a simpler, cost-effective means of protecting and enforcing patents in Europe. In 2022, the UP and UPC will supplement and strengthen the existing centralised European patent granting system. They will offer users of the patent system a cost-effective option for patent protection and dispute settlement across Europe. Topics of discussion will include:<\/p>\r\n      <ul>\r\n\t<li>Considering the costs and benefits of the system for patent applications<\/li>\r\n\t<li>Understanding the territorial scope of protection<\/li>\r\n\t<li>Predicting the impact to litigation and legal certainty<\/li>\r\n\t<li>Detailing the non-exclusive jurisdiction for all national validations of European patents<\/li>\r\n      <\/ul>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>1:00<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>Patent Enforcement Roundtable: Best Practices for Protecting Patent Rights and the Procedures to Enforce Them<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Antonio-Andrade-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Antonio-Andrade-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Antonio-Andrade-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Antonio-Andrade-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Antonio-Andrade.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tAnt\u00f3nio Andrade\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Abreu Advogados<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Laetitia-Benard-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Laetitia-Benard-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Laetitia-Benard-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Laetitia-Benard-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Laetitia-Benard.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tLa\u00ebtitia B\u00e9nard\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Allen &amp; Overy LLP<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Penny-Gilbert-80x80.gif\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Penny-Gilbert-80x80.gif 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Penny-Gilbert-130x130.gif 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Penny-Gilbert-60x60.gif 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Penny-Gilbert.gif 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tDr Penny Gilbert\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Powell Gilbert LLP<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n\r\n      <p>The European patent system is experiencing a major reformation centered on the idea of unifying the European patent system. For decades, patent enforcement decisions across jurisdictions within Europe have produced contradictory enforcement decisions across jurisdictions within Europe. There are important differences in the legal systems across the jurisdictions, and the strategies for practicing, protecting and enforcing must take these differences into account. Topics of discussion will include:<\/p>\r\n      <ul>\r\n\t<li>Comparing the timelines of proceedings across jurisdictions<\/li>\r\n\t<li>Reconciling the proportionality of defenses<\/li>\r\n\t<li>Predicting cross-border injunctions in the region<\/li>\r\n      <\/ul>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>2:15<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <p><em>1:1 Networking Break<\/em><\/p>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>3:00<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>The ABCs of SPCs: Scope, Duration and Requirements<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Steven-Baldwin-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Steven-Baldwin-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Steven-Baldwin-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Steven-Baldwin-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Steven-Baldwin.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tSteven Baldwin\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Kirkland &amp; Ellis LLP<\/h5>\r\n\t\t<\/div>\r\n<\/div>\r\n\r\n<!--<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Robert-Rodrigues-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Robert-Rodrigues-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Robert-Rodrigues-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Robert-Rodrigues-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Robert-Rodrigues.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tRobert Rodrigues\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Licks Attorneys<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>-->\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/02\/Sture-Rygaard-v2-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/02\/Sture-Rygaard-v2-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/02\/Sture-Rygaard-v2-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/02\/Sture-Rygaard-v2-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/02\/Sture-Rygaard-v2.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tSture Rygaard\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Pleasner<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n<ul>\r\n  <li>SPCs and Brexit<\/li>\r\n  <li>SPCs and the UPC<\/li>\r\n  <li> Update on recent case law\r\n    <ul>\r\n      <li>The CJEU Teva and Royalty Pharma<\/li>\r\n      <li>The MSD referral<\/li>\r\n      <li>The CJEU Santen-decision<\/li>\r\n      <li>SPC squatting <\/li>\r\n    <\/ul>\r\n  <\/li>\r\n  <\/ul><!-- <p>The United Kingdom has become a fully independent third country to the European Union. Implementing the trade agreement the UK has made with the EU represents a formidable challenge facing the pharmaceutical industry. Intellectual property and the pharmaceutical and biotech sectors are significant considerations for both the UK and the EU following Brexit. This session will shine a spotlight on the impact of Brexit on the pharmaceutical industry, focusing on the challenges ahead as well as areas of opportunity for the UK. Topics of discussion will include:<\/p>\r\n      <ul>\r\n\t<li>Outlining the implications of the rules of origin on the pharmaceutical and biotech industries<\/li>\r\n\t<li>Detailing the scope, relevant marketing authorization, and which patents can be used to obtain an SPC<\/li>\r\n\t<li>Considering areas where clarification from CJEU may still be required<\/li>\r\n      <\/ul>-->\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>3:45<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>Second Medical Use: Reconciling Infringement and Enforcement<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Burghart-Sara-80x80.jpg\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Burghart-Sara-80x80.jpg 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Burghart-Sara-130x130.jpg 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Burghart-Sara-60x60.jpg 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Burghart-Sara.jpg 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tSara Burghart\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Lead IP Litigation Counsel<br>Global Litigation &amp; Launch \u2013 Global IP<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Sandoz International GmbH (DEU)<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Miquel-Montana-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Miquel-Montana-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Miquel-Montana-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Miquel-Montana-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Miquel-Montana.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tMiquel Monta\u00f1\u00e1\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Clifford Chance S.l.<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jonas-Westerberg-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jonas-Westerberg-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jonas-Westerberg-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jonas-Westerberg-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jonas-Westerberg.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tJonas Westerberg\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Westerberg &amp; Partners Advokatbyr\u00e5 AB<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n      <p>Patents that cover new uses for previously known medicines are called &#8220;second medical use patents&#8221;. This form of patent protection has drawn much attention in recent years as courts around the world continue to adjudicate the complex questions that underlie them. Topics of discussion will include:<\/p>\r\n      <ul>\r\n\t<li>Understanding second medical use patents &#038; carve Out Strategies\r\n\t<ul>\r\n\t    <li>Clarifying the patentability of further medical use inventions<\/li>\r\n\t<\/ul><\/li>\r\n\t<li>Assessing the implications of second use patents for:\r\n\t<ul>\r\n\t    <li>Regulatory<\/li>\r\n\t    <li>Market Access<\/li>\r\n\t    <li>Legal<\/li>\r\n\t<\/ul><\/li>\r\n\t<li>Outlining the implications<\/li>\r\n\t<li>What form can second medical use claims take?<\/li>\r\n\t<li>What must be established for a second medical use patent to be infringed?<\/li>\r\n\t<li>How do you enforce a second medical use patent?<\/li>\r\n\t<li>Can you prevent off-label use?<\/li>\r\n      <\/ul>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>4:30<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <p><em>Conference Adjourns to Day Two<\/em><\/p>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n<\/table>\r\n\r\n<br>\r\n<br>\r\n<a id=\"day-two\" class=\"anchor\"><\/a>\r\n<h3><strong>Day Two<\/strong><\/h3>\r\n\r\n<table>\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:0px 0px 20px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\" width=\"80\">\r\n      <p>12:10<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>Opening Remarks and Recap from the Co-Chairs<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-80x80.jpg\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-80x80.jpg 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-130x130.jpg 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-60x60.jpg 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom.jpg 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tDominic Adair\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Bristows LLP (U.K)<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n\t<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-80x80.gif\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-80x80.gif 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-130x130.gif 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-60x60.gif 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden.gif 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tRuud van der Velden\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Hogan Lovells<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>12:15<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>Compulsory Licensing: Access to Medicines, The TRIPS Agreement and Vaccines<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Daan-de-Lange-80x80.jpg\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Daan-de-Lange-80x80.jpg 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Daan-de-Lange-130x130.jpg 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Daan-de-Lange-60x60.jpg 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Daan-de-Lange.jpg 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tDaan de Lange\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Brinkhof Advocaten<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Peter-Ling-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Peter-Ling-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Peter-Ling-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Peter-Ling-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Peter-Ling.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tPeter Ling\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Lenz &amp; Staehelin<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n      <ul>\r\n\t<li>Anticipating the potential impact of COVID-19 on IP legal matters, including patent protection for new uses and diagnostics\r\n\t<ul>\r\n\t    <li>How will IP protection work?<\/li>\r\n\t    <li>Can the distribution of a vaccine await licensing and agreement on pricing?<\/li>\r\n\t<\/ul><\/li>\r\n\t<li>What is the impact to IP licensing and enforcement?\r\n\t<ul>\r\n\t    <li>Compulsory licenses in Europe<\/li>\r\n\t<\/ul><\/li>\r\n\t<li>Assessing COVID-19 related antibody litigation<\/li>\r\n\t<li>Developing strategies for evolving to succeed in a post-COVID marketplace<\/li>\r\n      <\/ul>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>1:00<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>The Latest Developments Impacting Preliminary Injunctions in Europe<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-80x80.jpg\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-80x80.jpg 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-130x130.jpg 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom-60x60.jpg 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Adair-Dom.jpg 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tDominic Adair\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Bristows LLP (U.K)<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Selma-Unlu-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Selma-Unlu-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Selma-Unlu-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Selma-Unlu-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Selma-Unlu.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tSelma \u00dcnl\u00fc\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Senior Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">NSN Law Firm<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\t\t\r\n<div class=\"speaker-block\">\r\n\t\t\t\t\t\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Dr-Kai-Ruting-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Dr-Kai-Ruting-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Dr-Kai-Ruting-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Dr-Kai-Ruting-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Dr-Kai-Ruting.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tDr. Kai R\u00fcting\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Vossius &amp; Partner<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\r\n<\/div>\t\t\r\n\t\t<br>\r\n<br>\r\n\r\n\r\n      <p>In a recent referral to the CJEU, the Munich Regional Court opposed what it considered to be an overly restrictive practice of in proceedings for preliminary injunctions in patent matters. According to current practice, the patent must have survived nullity or opposition proceedings and hence a &#8220;second examination&#8221; of the patent (in addition to the granting procedure) as one of the conditions for a preliminary injunction (PI). This referral is astonishing (sensational?) as the Munich I Regional Court de facto lets the CJEU review a practice which originated from the D\u00fcsseldorf Court of Appeal. There is no decision of the CJEU yet but there is the chance that PIs may be obtained much easier in the future. There has, since long, been an exception to this rule of &#8220;second examination&#8221; in Generics-Originator proceedings, but this exception may be extended to further proceedings (originator-originator or Gx-Gx).<\/p>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>1:45<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <p><em>1:1 Networking Break<\/em><\/p>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>2:00<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>Patent Enforcement Liability Towards Third Parties: Liability and Unjust Enrichment on Retrospectively Invalid Patents<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Eran-Bareket-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Eran-Bareket-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Eran-Bareket-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Eran-Bareket-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Eran-Bareket.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tEran Bareket\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner, Head of Legal Practice<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Gilat, Bareket &amp; Co., Attorneys at Law<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jean-Hyacinthe-de-Mitry-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jean-Hyacinthe-de-Mitry-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jean-Hyacinthe-de-Mitry-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jean-Hyacinthe-de-Mitry-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/12\/Jean-Hyacinthe-de-Mitry.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tJean-Hyacinthe de Mitry\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Gide Loyrette Nouel A.A.R.P.I<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\t\t<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-80x80.gif\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-80x80.gif 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-130x130.gif 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden-60x60.gif 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/Ruud-van-der-Velden.gif 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tRuud van der Velden\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Partner<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Hogan Lovells<\/h5>\r\n\t\t\t<\/div>\r\n<\/div><br>\r\n<br>\r\n\r\n\t\t\r\n\r\n      <p>On October 14, 2020 the decision in Menzis\/AstraZeneca was issued by the District Court of The Hague. The District Court considered AstraZeneca liable for damages vis-\u00e0-vis health insurer Menzis because of AstraZeneca&#8217;s enforcement of a patent against a generic manufacturer. AstaZeneca was initially awarded an injunction which AstraZeneca enforced, but the patent was later revoked. The District Court held that AstraZeneca had been unjustifiably enriched at the expense of health insurer Menzis by enforcing the preliminary injunction based on the patent against the generic manufacturer. The District Court considered that the enforcement precluded Menzis from designating a generic quetiapine product as &#8216;preferred product&#8217; under its preference policy, so that Menzis had to reimburse the price of the originator product instead of a cheaper generic product.<\/p>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>2:45<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <h5>Mediation and Arbitration in European Pharma &#038; Biotech Patent Law<\/h5>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Maximilian-Haedicke-80x80.jpg\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Maximilian-Haedicke-80x80.jpg 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Maximilian-Haedicke-130x130.jpg 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Maximilian-Haedicke-60x60.jpg 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2019\/11\/Maximilian-Haedicke.jpg 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tProfessor Dr. Maximilian Haedicke\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Professor of Intellectual Property Law<\/h5>\r\n\t\t\t\t<h5 class=\"company\">Freiburg University<br><em style=\"font-weight:normal;\">(Former Judge at Higher Regional Court of Duesseldorf)<\/em><\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n<div class=\"flag-block person-profile-block\">\r\n\t<div class=\"flag-block-img person-profile-photo\">\r\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"80\" height=\"80\" src=\"\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Andre-Pohlmann-80x80.png\" class=\"attachment-speaker_flag_event_speakers size-speaker_flag_event_speakers wp-post-image\" alt=\"\" srcset=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Andre-Pohlmann-80x80.png 80w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Andre-Pohlmann-130x130.png 130w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Andre-Pohlmann-60x60.png 60w, https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2021\/01\/Andre-Pohlmann.png 150w\" sizes=\"auto, (max-width: 80px) 100vw, 80px\" style=\"margin-top:-25px;\">\t\t\t<\/div>\r\n\t<div class=\"flag-block-body person-profile-info\">\r\n\t\t<h4 class=\"full-name\">\r\n\t\t\tAndr\u00e9 Pohlmann\t\t<\/h4>\r\n\t\t\t<h5 class=\"job-title\">Member of the 5th Board of Appeal<\/h5>\r\n\t\t\t\t<h5 class=\"company\">European Union Intellectual Property Office<\/h5>\r\n\t\t\t<\/div>\r\n<\/div>\r\n\r\n      <ul>\r\n\t<li>Understanding how BoA and the EUIPO helps with ADR\r\n\t<ul>\r\n\t    <li>ADRs in the EUIPO Boards of Appeal<\/li>\r\n\t    <li>Assisted Negotiation and Expert Determination<\/li>\r\n\t    <li>Effective Dispute Resolution (EDR)<\/li>\r\n\t    <li>Co-mediation mechanisms<\/li>\r\n\t    <li>ADR Cooperation Initiatives<\/li>\r\n\t<\/ul><\/li>\r\n\t<li>Detailing why parties should consider using EUIPO ADR mechanisms\r\n\t<ul>\r\n\t    <li>Combining parallel disputes at national and international levels into one resolution<\/li>\r\n\t    <li>Avoiding complex litigation proceedings<\/li>\r\n\t    <li>Achieving quicker, more efficient outcomes in a cost-effective way<\/li>\r\n\t<\/ul><\/li>\r\n      <\/ul>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td colspan=\"2\">\r\n      <hr style=\"margin:20px 0px;\">\r\n    <\/td>\r\n  <\/tr>\r\n\r\n  <tr>\r\n    <td valign=\"top\">\r\n      <p>3:30<\/p>\r\n    <\/td>\r\n    <td valign=\"top\">\r\n      <p><em>Conference Concludes<\/em><\/p>\r\n    <\/td>\r\n  <\/tr>\r\n\r\n<\/table>\r\n\r\n<br>\r\n<br>\r\n<div class=\"row vertical-spacer-half\">\r\n  <div class=\"col-xs-12 col-md-12\">\r\n    <div class=\"bg-light text-center\" style=\"padding:40px 0px;\">\r\n\r\n      <div class=\"row\">\r\n        <div class=\"col-xs-12 col-md-8 col-md-offset-2\">\r\n          <h5>Interested in learning more about the virtual platform?<\/h5>\r\n          <a href=\"..\/livestream\/\" class=\"btn btn-sm btn-secondary\">Learn More<\/a>\r\n        <\/div>\r\n      <\/div>\r\n\r\n    <\/div>\r\n  <\/div>\r\n<\/div>","protected":false},"excerpt":{"rendered":"Day One&nbsp;&nbsp;|&nbsp;&nbsp;Day Two 12:10 Opening Remarks from the Co-Chairs Dominic Adair Partner Bristows LLP (U.K) Ruud van der Velden Partner Hogan Lovells 12:15 UPC Think Tank: Ratification, Implementation, and Protocols Domien Op de Beeck Partner Bird &amp; Bird Jochen Herr Partner Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP The Unitary Patent and the Unified Patent&hellip;","protected":false},"author":3967,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1062","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prelude Summit | Pharma &amp; Biotech Patent Litigation in Europe<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prelude Summit | Pharma &amp; Biotech Patent Litigation in Europe\" \/>\n<meta property=\"og:description\" content=\"Day One&nbsp;&nbsp;|&nbsp;&nbsp;Day Two 12:10 Opening Remarks from the Co-Chairs Dominic Adair Partner Bristows LLP (U.K) Ruud van der Velden Partner Hogan Lovells 12:15 UPC Think Tank: Ratification, Implementation, and Protocols Domien Op de Beeck Partner Bird &amp; Bird Jochen Herr Partner Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP The Unitary Patent and the Unified Patent&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma &amp; Biotech Patent Litigation in Europe\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-24T17:57:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/\",\"url\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/\",\"name\":\"Prelude Summit | Pharma &amp; Biotech Patent Litigation in Europe\",\"isPartOf\":{\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg\",\"datePublished\":\"2022-01-26T20:07:53+00:00\",\"dateModified\":\"2022-02-24T17:57:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#primaryimage\",\"url\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg\",\"contentUrl\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prelude Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/#website\",\"url\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/\",\"name\":\"Pharma & Biotech Patent Litigation in Europe\",\"description\":\"Template used to create new conference sites\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prelude Summit | Pharma &amp; Biotech Patent Litigation in Europe","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/","og_locale":"en_US","og_type":"article","og_title":"Prelude Summit | Pharma &amp; Biotech Patent Litigation in Europe","og_description":"Day One&nbsp;&nbsp;|&nbsp;&nbsp;Day Two 12:10 Opening Remarks from the Co-Chairs Dominic Adair Partner Bristows LLP (U.K) Ruud van der Velden Partner Hogan Lovells 12:15 UPC Think Tank: Ratification, Implementation, and Protocols Domien Op de Beeck Partner Bird &amp; Bird Jochen Herr Partner Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP The Unitary Patent and the Unified Patent&hellip;","og_url":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/","og_site_name":"Pharma &amp; Biotech Patent Litigation in Europe","article_modified_time":"2022-02-24T17:57:50+00:00","og_image":[{"url":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/","url":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/","name":"Prelude Summit | Pharma &amp; Biotech Patent Litigation in Europe","isPartOf":{"@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg","datePublished":"2022-01-26T20:07:53+00:00","dateModified":"2022-02-24T17:57:50+00:00","breadcrumb":{"@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#primaryimage","url":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg","contentUrl":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-content\/uploads\/sites\/1562\/2022\/01\/630L22_virtual_email_1200x627_PreludeSummit.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/prelude-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/"},{"@type":"ListItem","position":2,"name":"Prelude Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/#website","url":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/","name":"Pharma & Biotech Patent Litigation in Europe","description":"Template used to create new conference sites","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-json\/wp\/v2\/pages\/1062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-json\/wp\/v2\/users\/3967"}],"replies":[{"embeddable":true,"href":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-json\/wp\/v2\/comments?post=1062"}],"version-history":[{"count":0,"href":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-json\/wp\/v2\/pages\/1062\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.c5-online.com\/pharma-biotech-patent-litigation\/wp-json\/wp\/v2\/media?parent=1062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}